Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

March 23, 2021

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

March 18, 2021

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021

March 11, 2021

Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference

February 23, 2021

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference

December 7, 2020

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

November 17, 2020

Relmada Therapeutics to Participate in Upcoming Investor Conferences

October 27, 2020

Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones

July 13, 2020

Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

June 23, 2020

Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms

June 9, 2020

Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

«...11 121314 15 16...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top